Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, Kenady D, Desimone P, Mohiuddin M. Arnold SM, et al. Among authors: desimone p. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1411-7. doi: 10.1016/j.ijrobp.2003.09.019. Int J Radiat Oncol Biol Phys. 2004. PMID: 15050317 Clinical Trial.
Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.
Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, Kudrimoti M, Dineen S, Tzeng CD, Hosein PJ. Peterson SL, et al. Among authors: desimone p. Anticancer Res. 2018 Jul;38(7):4035-4039. doi: 10.21873/anticanres.12692. Anticancer Res. 2018. PMID: 29970528 Free PMC article.
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.
Sharma A, Mani S, Hanna N, Guha C, Vikram B, Weichselbaum RR, Sparano J, Sood B, Lee D, Regine W, Muhodin M, Valentino J, Herman J, Desimone P, Arnold S, Carrico J, Rockich AK, Warner-Carpenter J, Barton-Baxter M. Sharma A, et al. Among authors: desimone p. Hum Gene Ther. 2001 Jun 10;12(9):1109-31. doi: 10.1089/104303401750214320. Hum Gene Ther. 2001. PMID: 11399232 No abstract available.
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T, Evars JP, Hrushesky WJ, Jolivet J. Ramanathan RK, et al. Among authors: desimone p. Clin Colorectal Cancer. 2008 Mar;7(2):134-9. doi: 10.3816/ccc.2008.n.018. Clin Colorectal Cancer. 2008. PMID: 18501073 Clinical Trial.
58 results